Eli Lilly and Company announced today that the European Commission has granted marketing authorisation (MA) for Taltz® (ixekizumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drug (DMARD) therapies.
“PsA affects up to 30% of people who are already living with psoriasis, said Arash Tahbaz, Senior Medical Director, Eli Lilly and Company UK and Northern Europe. “Symptoms often begin around a decade after the onset of psoriasis, and can severely impact people’s lives and ability to work. We are proud to be able to offer a new treatment option that addresses both the joint and skin symptoms of PsA.”
Ixekizumab is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. This is the second approved indication for ixekizumab in the EU. Ixekizumab was authorized for the treatment of adult patients with moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy in Europe in April 2016.